Semaglutide vs Tirzepatide: Weight Loss, Side Effects and Cost

Tirzepatide produced greater average weight loss than semaglutide in SURMOUNT-5: 20.2% versus 13.7% over 72 weeks. That 2025 trial enrolled adults with obesity without diabetes and compared maximum-tolerated weekly injections: tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg. It did not compare oral medicines, compounded products or the newer 7.2 mg Wegovy injection. The average result is useful evidence, but it does not establish which treatment you should take. Your prescriber also needs to consider the exact brand, medical indication, side effects, other medicines and access cost.

Quick answer by priority:

• •Weight-loss evidence: Read the trial comparison below, then compare Wegovy and Zepbound, the weight-management brands.
• •Compounded semaglutide: Check Embody’s current plans and total costs. A compounded offer is not evidence of equivalence to Wegovy.
• •Brand-name semaglutide: Compare NovoCare’s current Wegovy offers with Hers’ medication and membership costs, and read Hers’ FDA warning-letter record before choosing. Match the formulation, prescribed dose, introductory period and ongoing fees.
• •Side effects: Both can cause gastrointestinal symptoms. A group-level trial rate cannot predict which medicine you will tolerate better.
• •Heart or kidney disease: Compare the exact indications in the current Ozempic, Mounjaro and Wegovy labels with your clinician.
• •Prefer a pill? Our oral GLP-1 guide separates approved oral semaglutide and orforglipron from compounded tablets. They are not interchangeable with the injections in SURMOUNT-5.

This guide covers the active-ingredient comparison across all brands (Wegovy, Ozempic, Rybelsus vs Zepbound, Mounjaro), trial data, side effects, cost, and insurance coverage. For the brand-name-only comparison, see Wegovy vs Zepbound.

How Do Semaglutide and Tirzepatide Work?

The fundamental difference between semaglutide and tirzepatide comes down to receptor targets. Understanding this helps explain why their clinical results differ.

Semaglutide is a GLP-1 receptor agonist. It mimics a single gut hormone, glucagon-like peptide-1, that your body naturally releases after eating. By binding to GLP-1 receptors in the brain, gut, and pancreas, semaglutide suppresses appetite, slows gastric emptying (so you feel full longer), and improves blood sugar regulation. It was developed by Novo Nordisk and first approved by the FDA in 2017 (as Ozempic for Type 2 diabetes). The weight-loss version, Wegovy, was approved in June 2021.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, what researchers call a "twincretin." It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GIP is another incretin hormone involved in glucose metabolism, fat storage, and energy balance. By hitting two targets instead of one, tirzepatide engages additional metabolic pathways that semaglutide doesn't directly activate. It was developed by Eli Lilly and first approved in 2022 (as Mounjaro for Type 2 diabetes). Zepbound (the weight-loss brand) followed in November 2023.

The injections of both medicines are given weekly. Semaglutide also has daily oral formulations with separate dosing instructions. See the current Wegovy label rather than transferring an injection dose to a tablet.

Does Semaglutide or Tirzepatide Produce More Weight Loss?

The clearest weight-loss comparison is the randomized SURMOUNT-5 trial, published by Aronne and colleagues in 2025. It studied 751 adults with obesity without type 2 diabetes. Tirzepatide produced a larger average reduction, but the trial was open-label and funded by Eli Lilly.

This is evidence about specific treatments, not a promise that one person will lose a set amount. It also does not show how much weight a person with diabetes would lose. For the diabetes comparison, use Mounjaro vs Ozempic, which explains SURPASS-2 and its semaglutide 1 mg comparator.

How Do Heart, Kidney and Sleep-Apnea Indications Differ?

Compare the brand and indication, not a general claim that one molecule is “better for the heart.” The current Wegovy, Ozempic, Mounjaro and Zepbound labels cover different populations and outcomes.

Wegovy’s cardiovascular evidence includes SELECT, which studied semaglutide 2.4 mg injections in adults with established cardiovascular disease and overweight or obesity, without diabetes. The result does not become an Ozempic trial merely because both contain semaglutide.

Ozempic’s label includes cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, plus kidney-related risk reduction in adults with type 2 diabetes and chronic kidney disease.

Mounjaro’s August 2026 label now includes cardiovascular risk reduction for adults with type 2 diabetes at high cardiovascular risk. Its SURPASS-CVOT study compared tirzepatide with dulaglutide, not semaglutide. It cannot establish which of Mounjaro and Ozempic is superior for heart outcomes.

Zepbound has an indication for moderate to severe obstructive sleep apnea in adults with obesity. This is separate from weight-loss averages and does not establish that every compounded tirzepatide preparation treats sleep apnea.

Bring the relevant diagnosis and treatment goal to your prescriber. A price comparison should follow that decision rather than replace it.

Which Has More Side Effects: Semaglutide or Tirzepatide?

Both can cause nausea, vomiting, diarrhea and constipation. The SURMOUNT-5 abstract describes gastrointestinal events as the most common adverse events in both groups, usually mild to moderate and concentrated during dose escalation. That does not mean either medicine is automatically easier for you to tolerate.

The current Wegovy and Zepbound labels report side effects from their respective trials. Their tables use different study populations and dose schedules, so we do not turn those numbers into a blanket “better tolerated” recommendation.

If side effects are limiting treatment, tell your clinician what happened, when it started, your dose and any other medicines you use. Ask about the options before changing or stopping a prescription. Our side-effect management guide distinguishes day-to-day symptoms from signs that need care.

A different medicine may suit some patients, but this page cannot identify a safe switching dose. See the switching section below and our Zepbound side-effects guide.

Which Forms of Semaglutide and Tirzepatide Are Approved?

Semaglutide has oral and injectable branded formulations; the approved tirzepatide brands are injections. The Wegovy label now includes 25 mg daily tablet maintenance and a 7.2 mg injection option. Older comparisons describing 2.4 mg as the universal maximum or oral maintenance as “TBD” are out of date.

For dose schedules, use our Wegovy dosage guide and Mounjaro dosage guide alongside the prescribed product’s label. Foundayo contains orforglipron, a different molecule; it is not oral tirzepatide. Our oral GLP-1 guide also explains other semaglutide brands and formulations.

Some providers market compounded oral dissolving tirzepatide, including Wellorithm from $249/mo. Those products are not FDA-approved Mounjaro or Zepbound tablets, and the injection trial results above cannot be assigned to them. A similar ingredient name is not evidence of equivalent absorption, safety or effectiveness.

Can You Switch From Semaglutide to Tirzepatide?

A prescriber can assess a switch, but there is no simple milligram-for-milligram conversion between these medicines. A higher number on a tirzepatide pen does not mean it is an equivalent dose of semaglutide.

The Mounjaro and Wegovy labels use different dose schedules and formulations. Tell your clinician your current product, dose, last injection or tablet, side effects and other medicines. Ask for a written plan for the change rather than using a comparison table as dosing instructions.

Do not combine them on your own. The Zepbound label advises against coadministration with another tirzepatide-containing product or a GLP-1 receptor agonist.

How Do Semaglutide and Tirzepatide Costs Compare?

Compare the exact product, prescribed dose and payment route. The manufacturer amounts below reflect the dated checks stated in this section; eligibility and offer terms can change. A compounded introductory price is not a price for branded Wegovy or Zepbound.

For patients paying out of pocket, Eli Lilly's LillyDirect Zepbound lists a $299 starting-dose offer, with higher-dose and refill conditions, while Novo Nordisk's NovoCare listed the Wegovy pen at $199/month for the first two low-dose fills, then $349/month at standard strengths ($399 for HD) and pill from $149/month in the August 7 check; a prescription is required and pricing is dose-dependent. Telehealth services advertise compounded prices including Enhance MD from $99 for the first month, Shed at $299/month, and Sprout Health from $199 for the first month. Those listings do not establish that a particular pharmacy, prescription, or batch meets section 503A, section 503B, or state-law conditions; 503A pharmacies are state-licensed rather than FDA-registered. Hers lists Wegovy pill medication from $149 or pen from $199 plus required $39 first-month/$149 ongoing membership. Use our cost calculator to compare prices separately from regulatory and product-safety questions.

For insured patients, both manufacturers offer savings cards that can bring copays as low as $25/month with eligible commercial insurance. Which drug your plan prefers varies, some insurers have exclusive deals with Novo Nordisk, others with Lilly. The most reliable strategy is to ask your provider to check coverage for both and go with whichever is on your formulary.

Compounded telehealth offers often use a prepaid monthly equivalent rather than a recurring monthly charge. Our bmiMD pricing breakdown separates semaglutide from tirzepatide, month-to-month prices from prepaid totals, and introductory terms from longer commitments. Use that current pricing record rather than treating a copied promotional number as a guaranteed quote.

If you're uninsured or underinsured, compare your options carefully. FDA's shortage-based enforcement-discretion periods for semaglutide ended in 2025. Any current compounded preparation must independently satisfy the applicable 503A or 503B requirements and state law; availability or a documented clinical rationale alone does not establish compliance. See our compounded semaglutide crackdown guide for the regulatory framework, then use our provider rankings to compare advertised program prices separately from prescription and pharmacy evidence. Willow's $299/mo program is one advertised post-shortage price benchmark, not a compliance determination.

What Should You Discuss With Your Prescriber Before Choosing?

Start with the treatment goal, the exact product and a sustainable access plan. A greater trial average is one input; it does not outweigh a contraindication or tell you how you will respond.

Questions about semaglutide:

• •Does a particular semaglutide brand’s approved indication fit my diagnosis?
• •Would a tablet or an injection be appropriate, and what instructions differ? See oral versus injectable options.
• •Which product does my plan cover, at my prescribed dose and for my indication?
• •If I already take semaglutide, would changing brands or formulations require a new treatment plan?

Questions about tirzepatide:

• •Does Mounjaro or Zepbound fit my diagnosis and treatment goals?
• •What do the weight-loss results mean for someone with my medical history?
• •How would we assess side effects and decide whether to adjust treatment?
• •What is the full cost at the prescribed dose after any introductory offer?

Once the clinical options are clear, compare semaglutide programs, tirzepatide programs and the cost calculator. Check medication, route, fees and commitment together; the lowest headline price may refer to a different product.

Our program finder helps narrow shopping preferences. It cannot diagnose a condition, confirm clinical eligibility or prescribe a medicine. Our beginner’s GLP-1 guide explains the questions to bring to an appointment.

Sources